Literature DB >> 19900942

Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.

Shu-Pin Huang1, Li-Chia Huang, Wen-Chien Ting, Lu-Min Chen, Ta-Yuan Chang, Te-Ling Lu, Yu-Hsuan Lan, Chia-Chu Liu, Wen-Hui Yang, Hong-Zin Lee, Chi-Jeng Hsieh, Bo-Ying Bao.   

Abstract

Recent genomewide association studies have identified several prostate cancer susceptibility variants. However, the association between these variants and biochemical failure in prostate cancer patients receiving radical prostatectomy has not been determined. We systematically evaluated 20 prostate cancer-associated single-nucleotide polymorphisms in a cohort of 320 localized prostate cancer patients receiving radical prostatectomy. Each single-nucleotide polymorphism found to be associated with the recurrence of prostate-specific antigen was further analyzed by Kaplan-Meier analysis and Cox regression model. Three prostate cancer susceptibility single-nucleotide polymorphisms (rs1447295 at 8q24, rs7920517 and rs10993994 at 10q11) were associated with prostate-specific antigen recurrence (P < 0.02). Of these, rs7920517 and rs10993994, which were in strong linkage disequilibrium (r(2) = 0.91), also showed significant associations with poor prostate-specific antigen-free survival following radical prostatectomy (log-rank test; P < 0.01). The associations remained significant in our multivariate Cox proportional hazards analysis after adjusting for other clinicopathologic risk covariates (P < 0.01). In conclusion, loci associated with risk for prostate cancer, such as rs7920517 and rs10993994, might also be used to predict the recurrence of prostate-specific antigen in prostate cancer patients receiving radical prostatectomy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19900942     DOI: 10.1158/1055-9965.EPI-09-0665

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  43 in total

1.  Genome-wide detection of allelic genetic variation to predict biochemical recurrence after radical prostatectomy among prostate cancer patients using an exome SNP chip.

Authors:  Jong Jin Oh; Seunghyun Park; Sang Eun Lee; Sung Kyu Hong; Sangchul Lee; Hak Min Lee; Jung Keun Lee; Jin-Nyoung Ho; Sungroh Yoon; Seok-Soo Byun
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-13       Impact factor: 4.553

2.  Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence.

Authors:  Jiyoung Ahn; Adam S Kibel; Jong Y Park; Timothy R Rebbeck; Hanna Rennert; Janet L Stanford; Elaine A Ostrander; Stephen Chanock; Ming-Hsi Wang; Rama D Mittal; William B Isaacs; Elizabeth A Platz; Richard B Hayes
Journal:  Clin Cancer Res       Date:  2011-02-22       Impact factor: 12.531

3.  Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination.

Authors:  Brian T Helfand; Donghui Kan; Parth Modi; William J Catalona
Journal:  Prostate       Date:  2010-09-21       Impact factor: 4.104

4.  Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer.

Authors:  Jiunn-Bey Pao; Ying-Pi Yang; Chun-Nung Huang; Shu-Pin Huang; Tzyh-Chyuan Hour; Ta-Yuan Chang; Yu-Hsuan Lan; Te-Ling Lu; Hong-Zin Lee; Shin-Hun Juang; Chao-Yuan Huang; Bo-Ying Bao
Journal:  World J Urol       Date:  2011-12-23       Impact factor: 4.226

5.  Prostate cancer susceptibility variants confer increased risk of disease progression.

Authors:  Iona Cheng; Sarah J Plummer; Christine Neslund-Dudas; Eric A Klein; Graham Casey; Benjamin A Rybicki; John S Witte
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-22       Impact factor: 4.254

6.  Susceptibility loci associated with prostate cancer progression and mortality.

Authors:  David J Gallagher; Joseph Vijai; Angel M Cronin; Jasmine Bhatia; Andrew J Vickers; Mia M Gaudet; Samson Fine; Victor Reuter; Howard I Scher; Christer Halldén; Ana Dutra-Clarke; Robert J Klein; Peter T Scardino; James A Eastham; Hans Lilja; Tomas Kirchhoff; Kenneth Offit
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

Review 7.  The role of BRCA1 and BRCA2 in prostate cancer.

Authors:  Elena Castro; Rosalind Eeles
Journal:  Asian J Androl       Date:  2012-04-23       Impact factor: 3.285

8.  Association between the polygenic liabilities for prostate cancer and breast cancer with biochemical recurrence after radical prostatectomy for localized prostate cancer.

Authors:  Shi-Heng Wang; Shu-Pin Huang; Yi-Jiun Pan; Po-Chang Hsiao; Chia-Yang Li; Lih-Chyang Chen; Chia-Cheng Yu; Chao-Yuan Huang; Victor C Lin; Te-Ling Lu; Bo-Ying Bao
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

9.  Gene panel model predictive of outcome in patients with prostate cancer.

Authors:  Nadège Rabiau; Yann Dantal; Laurent Guy; Marjolaine Ngollo; Aslihan Dagdemir; Jean-Louis Kemeny; Benoît Terris; Annick Vieillefond; Jean-Paul Boiteux; Yves-Jean Bignon; Dominique Bernard-Gallon
Journal:  OMICS       Date:  2013-06-11

Review 10.  The genetic epidemiology of prostate cancer and its clinical implications.

Authors:  Rosalind Eeles; Chee Goh; Elena Castro; Elizabeth Bancroft; Michelle Guy; Ali Amin Al Olama; Douglas Easton; Zsofia Kote-Jarai
Journal:  Nat Rev Urol       Date:  2013-12-03       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.